M

MGI Tech Co Ltd
SSE:688114

Watchlist Manager
MGI Tech Co Ltd
SSE:688114
Watchlist
Price: 51.7 CNY -0.58% Market Closed
Market Cap: 21.5B CNY
Have any thoughts about
MGI Tech Co Ltd?
Write Note

Net Margin
MGI Tech Co Ltd

-33.9%
Current
1%
Average
0.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.9%
=
Net Income
-873.1m
/
Revenue
2.6B

Net Margin Across Competitors

Country CN
Market Cap 21.3B CNY
Net Margin
-34%
Country US
Market Cap 1.2T USD
Net Margin
9%
Country US
Market Cap 202.3B USD
Net Margin
14%
Country US
Market Cap 166.6B USD
Net Margin
18%
Country KR
Market Cap 66.8T KRW
Net Margin
24%
Country CH
Market Cap 38.4B CHF
Net Margin
9%
Country US
Market Cap 38.8B USD
Net Margin
20%
Country US
Market Cap 36.2B USD
Net Margin
9%
Country US
Market Cap 27B USD
Net Margin
21%
Country US
Market Cap 24B USD
Net Margin
17%
Country CN
Market Cap 164.4B CNY
Net Margin
21%
No Stocks Found

MGI Tech Co Ltd
Glance View

Market Cap
21.3B CNY
Industry
Life Sciences Tools & Services

MGI Tech Co Ltd, a key player in the genomics industry, emerged from the bustling biotech hub of Shenzhen, China, and swiftly carved a niche for itself with cutting-edge sequencing technology. Founded in 2016 as a subsidiary of BGI Group, MGI has dedicated itself to developing advanced genetic sequencing platforms and related products. The company’s mission is clear: to empower life science research and healthcare by providing innovative tools that make sequencing faster, cheaper, and more accessible. At the core of MGI’s success is their proprietary platform sequencing technology, known as the DNBSEQ™, which has garnered attention for its high throughput and accuracy. This technology is pivotal to their business model, as it significantly reduces the cost of sequencing, giving MGI a competitive edge in the market. MGI's business thrives on a dual revenue stream, primarily from the sale of their state-of-the-art sequencing devices and from providing sequencing services. Their portfolio of sequencing platforms, ranging from benchtop sequencers like the MGISEQ-2000 to large-scale units, caters to a diverse clientele, including research institutions, healthcare providers, and industry giants. The company supports this with a robust after-sales service and supply of consumables required for continuous operation, such as reagents and sequencing kits. By embedding itself deeply into the operational frameworks of its clients, MGI not only boosts its device sales but also ensures a persistent revenue flow from ongoing service and supplies. This business model positions MGI Tech Co Ltd as a formidable force, continually driving advancements in genome technology while expanding its global footprint.

Intrinsic Value
39.36 CNY
Overvaluation 24%
Intrinsic Value
Price
M

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-33.9%
=
Net Income
-873.1m
/
Revenue
2.6B
What is the Net Margin of MGI Tech Co Ltd?

Based on MGI Tech Co Ltd's most recent financial statements, the company has Net Margin of -33.9%.